Cargando…

A pilot study on the impact of known drug-drug interactions in cancer patients

BACKGROUND: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at high risk of such interactions because they commonly receive multiple medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ussai, Silvia, Petelin, Riccardo, Giordano, Antonio, Malinconico, Mario, Cirillo, Donatella, Pentimalli, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547416/
https://www.ncbi.nlm.nih.gov/pubmed/26303220
http://dx.doi.org/10.1186/s13046-015-0201-2
_version_ 1782387068926689280
author Ussai, Silvia
Petelin, Riccardo
Giordano, Antonio
Malinconico, Mario
Cirillo, Donatella
Pentimalli, Francesca
author_facet Ussai, Silvia
Petelin, Riccardo
Giordano, Antonio
Malinconico, Mario
Cirillo, Donatella
Pentimalli, Francesca
author_sort Ussai, Silvia
collection PubMed
description BACKGROUND: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at high risk of such interactions because they commonly receive multiple medications. Moreover, most cancer patients are elderly and require additional medications for comorbidities. Aim of this preliminary observational study was to evaluate the incidence of well known and established DDIs in a cohort of cancer outpatients undergoing multiple treatments. METHODS: Anamnestic and clinical data were collected for 64 adult patients in the ambulatory setting with malignant solid tumors who were receiving systemic anticancer treatment. Patients also declared all drugs prescribed by other specialists or self-taken in the previous 2 weeks. DDIs were divided into two different groups: ‘neoplastic DDIs’ (NDDIs), involving antitumoral drugs, and ‘not neoplastic DDIs’ (nDDIs), involving all other classes of drugs. The severity of DDIs was classified as major, moderate and minor, according to the ‘Institute for Pharmacological Research Mario Negri’ definition. RESULTS: About 34 % of cancer outpatients within our cohort were prescribed/assumed interacting drug combinations. The most frequent major NDDIs involved the anticoagulant warfarin (33 % of total NDDIs) that, in association with tamoxifen, or capecitabine and paclitaxel, increased the risk of haemorrhage. About 60 % of nDDIs involved acetylsalicylic acid. CONCLUSIONS: Overall, 16 % of DDIs were related to an A-level strength of recommendation to be avoided. The lack of effective communication among specialists and patients might have a role in determining therapeutic errors. Our pilot study, although limited by a small cohort size, highlights the urgent need of implementing the clinical management of cancer outpatients with new strategies to prevent or minimize potential harmful DDIs.
format Online
Article
Text
id pubmed-4547416
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45474162015-08-25 A pilot study on the impact of known drug-drug interactions in cancer patients Ussai, Silvia Petelin, Riccardo Giordano, Antonio Malinconico, Mario Cirillo, Donatella Pentimalli, Francesca J Exp Clin Cancer Res Research BACKGROUND: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at high risk of such interactions because they commonly receive multiple medications. Moreover, most cancer patients are elderly and require additional medications for comorbidities. Aim of this preliminary observational study was to evaluate the incidence of well known and established DDIs in a cohort of cancer outpatients undergoing multiple treatments. METHODS: Anamnestic and clinical data were collected for 64 adult patients in the ambulatory setting with malignant solid tumors who were receiving systemic anticancer treatment. Patients also declared all drugs prescribed by other specialists or self-taken in the previous 2 weeks. DDIs were divided into two different groups: ‘neoplastic DDIs’ (NDDIs), involving antitumoral drugs, and ‘not neoplastic DDIs’ (nDDIs), involving all other classes of drugs. The severity of DDIs was classified as major, moderate and minor, according to the ‘Institute for Pharmacological Research Mario Negri’ definition. RESULTS: About 34 % of cancer outpatients within our cohort were prescribed/assumed interacting drug combinations. The most frequent major NDDIs involved the anticoagulant warfarin (33 % of total NDDIs) that, in association with tamoxifen, or capecitabine and paclitaxel, increased the risk of haemorrhage. About 60 % of nDDIs involved acetylsalicylic acid. CONCLUSIONS: Overall, 16 % of DDIs were related to an A-level strength of recommendation to be avoided. The lack of effective communication among specialists and patients might have a role in determining therapeutic errors. Our pilot study, although limited by a small cohort size, highlights the urgent need of implementing the clinical management of cancer outpatients with new strategies to prevent or minimize potential harmful DDIs. BioMed Central 2015-08-25 /pmc/articles/PMC4547416/ /pubmed/26303220 http://dx.doi.org/10.1186/s13046-015-0201-2 Text en © Ussai et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ussai, Silvia
Petelin, Riccardo
Giordano, Antonio
Malinconico, Mario
Cirillo, Donatella
Pentimalli, Francesca
A pilot study on the impact of known drug-drug interactions in cancer patients
title A pilot study on the impact of known drug-drug interactions in cancer patients
title_full A pilot study on the impact of known drug-drug interactions in cancer patients
title_fullStr A pilot study on the impact of known drug-drug interactions in cancer patients
title_full_unstemmed A pilot study on the impact of known drug-drug interactions in cancer patients
title_short A pilot study on the impact of known drug-drug interactions in cancer patients
title_sort pilot study on the impact of known drug-drug interactions in cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547416/
https://www.ncbi.nlm.nih.gov/pubmed/26303220
http://dx.doi.org/10.1186/s13046-015-0201-2
work_keys_str_mv AT ussaisilvia apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT petelinriccardo apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT giordanoantonio apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT malinconicomario apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT cirillodonatella apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT pentimallifrancesca apilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT ussaisilvia pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT petelinriccardo pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT giordanoantonio pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT malinconicomario pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT cirillodonatella pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients
AT pentimallifrancesca pilotstudyontheimpactofknowndrugdruginteractionsincancerpatients